Evidence map›Paper›PMID 29790003›Full record

ReviewImmunologic research2018

Rationalizing the path to a universal graft recipient.

Melvin Cohn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Melvin CohnConceptual Immunology Group, The Salk Institute, 10010 N. Torrey Pines Rd., La Jolla, CA, 92037, USA. cohn@salk.edu.ORCID http://orcid.org/0000-0003-0191-0260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this essay is to take the reader through the logic that would predict universal graft acceptance. The story begins with what we learned from an experiment performed 65 years ago and develops that information in greater depth. The pathway of the analysis leads to the conclusion that controlling the immune system at the level of the T-helper would be the best way to approach a general solution to the problem of graft acceptance.

Indexed as

AnimalsGraft RejectionGraft SurvivalGraft vs Host DiseaseHumansImmune SystemSignal TransductionT-Lymphocytes, Helper-InducerTransplantation ImmunologyChimerismSuppressionTCR structure-functionTissue transplantation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.